244 related articles for article (PubMed ID: 29145597)
1. Laboratory Testing of a Cohort of Commercially Insured Users of HIV Preexposure Prophylaxis in the United States, 2011-2015.
Huang YA; Tao G; Samandari T; Hoover KW
J Infect Dis; 2018 Jan; 217(4):617-621. PubMed ID: 29145597
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral Medications for the Prevention of HIV Infection: A Clinical Approach to Preexposure Prophylaxis, Postexposure Prophylaxis, and Treatment as Prevention.
Heendeniya A; Bogoch II
Infect Dis Clin North Am; 2019 Sep; 33(3):629-646. PubMed ID: 31239092
[TBL] [Abstract][Full Text] [Related]
3. Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation.
Marcus JL; Hurley LB; Hare CB; Nguyen DP; Phengrasamy T; Silverberg MJ; Stoltey JE; Volk JE
J Acquir Immune Defic Syndr; 2016 Dec; 73(5):540-546. PubMed ID: 27851714
[TBL] [Abstract][Full Text] [Related]
4. Summary of German-Austrian HIV PrEP guideline.
Spinner CD; Lang GF; Boesecke C; Jessen H; Schewe K;
HIV Med; 2019 Jul; 20(6):368-376. PubMed ID: 31140708
[TBL] [Abstract][Full Text] [Related]
5. Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons-United States, 2010-2014.
Wu H; Mendoza MC; Huang YA; Hayes T; Smith DK; Hoover KW
Clin Infect Dis; 2017 Jan; 64(2):144-149. PubMed ID: 27986691
[TBL] [Abstract][Full Text] [Related]
6. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
[TBL] [Abstract][Full Text] [Related]
7. Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation.
Landovitz RJ
Top Antivir Med; 2015; 23(2):85-90. PubMed ID: 26200708
[TBL] [Abstract][Full Text] [Related]
8. ARV-based HIV prevention for women - where we are in 2014.
Mastro TD; Sista N; Abdool-Karim Q
J Int AIDS Soc; 2014; 17(3 Suppl 2):19154. PubMed ID: 25224614
[TBL] [Abstract][Full Text] [Related]
9. Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa.
Musinguzi N; Muganzi CD; Boum Y; Ronald A; Marzinke MA; Hendrix CW; Celum C; Baeten JM; Bangsberg DR; Haberer JE;
AIDS; 2016 Apr; 30(7):1121-9. PubMed ID: 26785125
[TBL] [Abstract][Full Text] [Related]
10. Missed Opportunities to Prescribe Preexposure Prophylaxis in South Carolina, 2013-2016.
Smith DK; Chang MH; Duffus WA; Okoye S; Weissman S
Clin Infect Dis; 2019 Jan; 68(1):37-42. PubMed ID: 29790923
[TBL] [Abstract][Full Text] [Related]
11. No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting.
Volk JE; Marcus JL; Phengrasamy T; Blechinger D; Nguyen DP; Follansbee S; Hare CB
Clin Infect Dis; 2015 Nov; 61(10):1601-3. PubMed ID: 26334052
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.
van der Straten A; Stadler J; Luecke E; Laborde N; Hartmann M; Montgomery ET;
J Int AIDS Soc; 2014; 17(3 Suppl 2):19146. PubMed ID: 25224610
[TBL] [Abstract][Full Text] [Related]
13. Evolving Models and Ongoing Challenges for HIV Preexposure Prophylaxis Implementation in the United States.
Mayer KH; Chan PA; R Patel R; Flash CA; Krakower DS
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):119-127. PubMed ID: 29084044
[TBL] [Abstract][Full Text] [Related]
14. Trends in Recommended Screening and Monitoring Tests for Users of HIV Pre-Exposure Prophylaxis Before and During the COVID-19 Pandemic.
Unigwe IF; Cook RL; Janelle JW; Park H
AJPM Focus; 2023 Dec; 2(4):100134. PubMed ID: 37790950
[TBL] [Abstract][Full Text] [Related]
15. The preexposure prophylaxis revolution; from clinical trials to programmatic implementation.
Mugo NR; Ngure K; Kiragu M; Irungu E; Kilonzo N
Curr Opin HIV AIDS; 2016 Jan; 11(1):80-6. PubMed ID: 26575147
[TBL] [Abstract][Full Text] [Related]
16. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
Haberer JE
Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638
[TBL] [Abstract][Full Text] [Related]
17. Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States.
Jenness SM; Goodreau SM; Rosenberg E; Beylerian EN; Hoover KW; Smith DK; Sullivan P
J Infect Dis; 2016 Dec; 214(12):1800-1807. PubMed ID: 27418048
[TBL] [Abstract][Full Text] [Related]
18. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Parikh UM; Mellors JW
Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
[TBL] [Abstract][Full Text] [Related]
19. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada.
Karris MY; Beekmann SE; Mehta SR; Anderson CM; Polgreen PM
Clin Infect Dis; 2014 Mar; 58(5):704-12. PubMed ID: 24319083
[TBL] [Abstract][Full Text] [Related]
20. What does preexposure prophylaxis mean for treatment; what does treatment mean for preexposure prophylaxis?
Venter WD
Curr Opin HIV AIDS; 2016 Jan; 11(1):35-40. PubMed ID: 26545265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
